OncoMatch/Clinical Trials/NCT06699602
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Is NCT06699602 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Fianlimab for renal cell carcinoma.
Treatment: Cemiplimab · Fianlimab — The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior receipt of any systemic therapy for renal cell carcinoma.
Cannot have received: immune checkpoint inhibitor
Prior receipt of any immune checkpoint inhibitor therapy for any indication.
Lab requirements
Blood counts
ANC ≥ 1500/μL (no G-CSF within 2 weeks); WBC ≥ 2500/μL and ≤ 15,000/μL (no G-CSF); absolute lymphocyte count ≥ 500/μL; platelet count ≥ 100,000/μL (no transfusion within 2 weeks); hemoglobin ≥ 9.0 g/dL (no transfusion within 2 weeks)
Kidney function
Creatinine ≤ 2.0 x ULN or eGFR ≥ 40 mL/min using CKD-EPI formula
Liver function
ALT, AST, and ALP ≤ 3 X ULN; ALP ≤ 5 x ULN if patient has documented bone metastases; serum bilirubin ≤ 1.5 x ULN (≤ 2 x ULN if Gilbert disease)
Patients must have adequate organ and bone marrow function, defined by the following laboratory results obtained within 14 days prior to the first study treatment: ... (see full criteria for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify